Iroko Pharmaceuticals signed a licensing agreement with Aspen Pharma for the exclusive rights to register and market ZORVOLEX (diclofenac) capsules in Australia and New Zealand.
Aspen Pharma will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication.
Iroko will continue to retain all marketing rights to ZORVOLEX in the U.S., where ZORVOLEX is approved by the United States Food and Drug Administration for the management of mild to moderate acute pain and osteoarthritis pain.
ZORVOLEX is not currently approved for marketing in any other country.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity